Successful treatment of juvenile generalized pustular psoriasis with infliximab therapy: two case reports

Lu, Jiajing; Liu, Ying; Yu, Na; Chen, Fujuan; Ding, Yangfeng; Xie, Yonggang

doi:10.1177/0300060520912091

Cited by 6 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Infliximab has been reported to be safe and effective for the management of GPP during pregnancy 54–57 and for pediatric patients. 58–61 …”

Section: Resultsmentioning

confidence: 99%

“…[39][40][41][42][43][44][45][46][47][48][49][50][51][52][53] Infliximab has been reported to be safe and effective for the management of GPP during pregnancy [54][55][56][57] and for pediatric patients. [58][59][60][61] Finally, 9 cases of paradoxical GPP developed during treatment with infliximab have been reported. [62][63][64][65][66][67][68]…”

Section: Infliximabmentioning

confidence: 99%

See 1 more Smart Citation

Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?

Megna¹,

Camela²,

Ruggiero³

et al. 2023

CCID

View full text Add to dashboard Cite

Generalized pustular psoriasis (GPP) is a severe and rare form of psoriasis, being a potentially life-threatening condition, characterized by recurring episodes or flares of widespread cutaneous erythema with macroscopic sterile pustules. An irregular innate immune response is linked to GPP, which is considered an auto-inflammatory disorder, while innate and adaptive immunopathogenic responses are involved in psoriasis pathogenesis. In consequence, different cytokine cascades have been suggested to be mainly involved in the pathogenesis of each different psoriasis form, with the interleukin (IL)23/IL17 axis implied in plaque psoriasis, and the IL36 pathway in the GPP. As regards GPP treatment, conventional systemic drugs available for plaque psoriasis are usually used as the first-line treatment option. However, contraindications and adverse events often limit the use of these therapies. In this scenario, biologic drugs may represent a promising treatment option. To date, even if 12 different biologics have been approved for plaque psoriasis, none of these is approved for GPP where they are employed off-label. Recently, spesolimab, an anti-IL36 receptor monoclonal antibody, has been recently approved for GPP. The purpose of this article is to assess the current literature about the use of biological therapies for the treatment of GPP to establish the basis for a shared GPP management algorithm.

show abstract

“…Infliximab has been reported to be safe and effective for the management of GPP during pregnancy 54–57 and for pediatric patients. 58–61 …”

Section: Resultsmentioning

confidence: 99%

Section: Infliximabmentioning

confidence: 99%

Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?

Megna¹,

Camela²,

Ruggiero³

et al. 2023

CCID

View full text Add to dashboard Cite

show abstract

“…A similar effect was also observed in Chinese children. Lu et al 47 . treated two Chinese juveniles with GPP successfully, one achieved complete resolution within 2 weeks, and one had their disease controlled within 72 h. No relapse or exacerbation occurred in the two juveniles during 12 months.…”

Section: Systemic Treatmentsmentioning

confidence: 99%

“…46 A similar effect was also observed in Chinese children. Lu et al 47 treated two Chinese juveniles with GPP successfully, one achieved complete resolution within 2 weeks, and one had their disease controlled within 72 h. No relapse or exacerbation occurred in the two juveniles during 12 months. Pan et al 48 described a Chinese juvenile with GPP and IL36RN c.115+6T > C homozygous mutation who had a good rapid response to short-term infliximab and had no relapse for 21 months.…”

Section: Tnf-α Blocking Agentsmentioning

confidence: 99%

The update of treatment strategies in pediatrics with generalized pustular psoriasis in China

Chen,

Xiang,

Wang

et al. 2023

Pediatric Investigation

View full text Add to dashboard Cite

Generalized pustular psoriasis (GPP) is a severe subtype of psoriasis, commonly combined with systemic inflammation. Gene mutations have been found to be associated with GPP and vary by ethnicity. Systemic treatments are usually required for the severity and potential complications of GPP. However, there is no common consensus in China, especially among pediatric patients, whose data are scarce. Acitretin, methotrexate, and cyclosporine are widely used in pediatrics with GPP, while the adverse effects should be highlighted. The emergence of different biological agents brings us into a new era. This article discusses the genetic background of Chinese patients and demonstrates the evidence of treatment in pediatrics with GPP.

show abstract

Clinical advances in biological therapy for generalized pustular psoriasis: a review

Hsieh,

Tsai

2024

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

Successful treatment of juvenile generalized pustular psoriasis with infliximab therapy: two case reports

Cited by 6 publications

References 16 publications

Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?

Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?

The update of treatment strategies in pediatrics with generalized pustular psoriasis in China

Clinical advances in biological therapy for generalized pustular psoriasis: a review

Contact Info

Product

Resources

About